Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
Portfolio Pulse from Vandana Singh
Enliven Therapeutics Inc (NASDAQ:ELVN) released Phase 1 clinical trial data for ELVN-001, a kinase inhibitor targeting BCR-ABL gene fusion in CML patients. The trial showed a 44% major molecular response rate at 12 weeks, with no significant toxicities, supporting once-daily dosing. ELVN shares surged 23.60% to $24.50.
April 11, 2024 | 5:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ELVN-001 Phase 1 trial data shows a 44% major molecular response in CML patients, with no significant toxicities, supporting its potential as a treatment. Shares rose 23.60% to $24.50.
The positive clinical trial results for ELVN-001 demonstrate significant potential for treating CML, addressing limitations of current treatments. The data showing a high response rate and good tolerability likely contributed to the surge in ELVN's stock price, reflecting investor optimism about the drug's commercial prospects.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100